• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Diagnostic Imaging's Top Five Prostate Imaging Content of 2024

News
Slideshow

Catch up on the most well-viewed prostate imaging content from 2024.

As we come to the end of 2024, we take a look back at the most well-read prostate imaging content with topics ranging from predictive factors for metastatic prostate cancer to the use of prostate MRI for active surveillance and PSMA PET/CT-guided radiotherapy for oligometastatic prostate cancer. Review the slideshow below to see highlighted prostate imaging content from the past year.

Recent Videos
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
Related Content
Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Jeff Hall
January 29th 2025
Article

For patients with newly diagnosed obstructive coronary artery disease (CAD), a multimodal machine learning model offered an 86 percent AUC for predicting MACE, which was 10 percent higher than CCTA alone and over 35 percent higher than the Framingham Risk Score.

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

Matt Hoffman
July 3rd 2021
Podcast

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

FDA Clears AI-Enhanced Portfolio of Ultrasound Systems for Women with High-Risk Pregnancies

FDA Clears AI-Enhanced Portfolio of Ultrasound Systems for Women with High-Risk Pregnancies

Jeff Hall
January 28th 2025
Article

An array of AI-powered features and automated tools may lead to improved workflow and image quality with the Voluson Expert 22, 20 and 18 ultrasound systems.

The Reading Room: Potential fMRI Alternative -- fPACT

The Reading Room: Potential fMRI Alternative -- fPACT

Whitney J. Palmer
June 23rd 2021
Podcast

Drs. Charles Liu and Jonathan Russin discuss the benefits and potential of fPACT, the alternative to functional MRI.

Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC

Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC

Jeff Hall
January 24th 2025
Article

Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.

Study: Contrast-Enhanced Ultrasound May Improve LI-RADS Assessment of High-Risk Indeterminate Liver Lesions

Study: Contrast-Enhanced Ultrasound May Improve LI-RADS Assessment of High-Risk Indeterminate Liver Lesions

Jeff Hall
January 23rd 2025
Article

For patients previously assessed with LI-RADS LR-4 and LR-M presentations based on MRI or CT findings, the use of contrast-enhanced ultrasound led to 30 percent of these patients having LR-5 assessments definitive for hepatocellular carcinoma.

© 2025 MJH Life Sciences

All rights reserved.